A review of exemestane in the management of breast cancer

Bibliography

• PARKIN DM, BRAY Fl, DEVESA SS: Cancer burden in the year 2000. The global picture. Eur. J. Cancer. (2001) 37\(Suppl. 8):4–66.
   Google Scholar
• NANDI S, GUZMAN RC, YANG J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying. Proc. Natl. Acad. Sci. USA (1995) 92(9):3650–3657.
   PubMed Web of Science ®Google Scholar
• YAGER JD, LIEHR JG: Molecular mechanisms of estrogen carcinogenesis. Ann. Rev. Phannacol. Toxicol. (1996) 36:203–232.
   PubMed Web of Science ®Google Scholar
• HARVELL DM, STRECKER TE, TOCHACEK M et al: Rat strain-specific actions of 170-estradiol in the mammary: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc. Natl. Acad. Sci. USA (2000) 97(6):2779–2784.
   PubMedGoogle Scholar
• DEVANESAN P, SANTEN RJ, BOCCHINFUSO WP, KORACH KS, ROGAN EG, CAVALIERI E: Catechol estrogen metabolites and conjugates in tumors and hyperplastic tissue from estrogen receptor-a knock-out (ERK0)/Wnt-1 mice: implications for initiation of mammary tumors. Carcinogenesis (2001) 22(9):1573–1576.
   PubMedGoogle Scholar
• WARD FIW: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. BE Med. J. (1973) 1(5844):13–14.
   PubMedGoogle Scholar
• PRITCHARD KI, THOMSON DB, MYERS RE, SUTHERLAND DJ, MOBBS BG, MEAKIN JW: Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat. Rep. (1980) 64(6-7):787–796.
   PubMedGoogle Scholar
• EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet (2005) 365(9472):1687–1717.
   PubMedGoogle Scholar
• CASH R, BROUGH AJ, COHEN MN, SATOH PS: Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. I. Clin. Endocrinol Metab. (1967) 27:1239–1248.
   PubMed Web of Science ®Google Scholar
• SIMPSON ER, ZHAO Y, AGARWAL VR et al.: Aromatase expression in health and disease. Recent Frog. Harm Res. (1997) 52:185–213.
   PubMedGoogle Scholar
• SANTEN RJ, MARTEL J, M et al: Stromal spindle cells contain aromatase in human breast tumors. I Clin. Endocrinol Metab. (1994) 79(2):627–632.
   PubMed Web of Science ®Google Scholar
• BEZWODA WR, GUDGEON A, FALKSON G, JORDAAN JP, GOEDHALS L: Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer. Oncology. (1998) 55(5):416–420.
   PubMed Web of Science ®Google Scholar
• THURLIMANN B, CASTIGLIONE M, HSU-SCHMITZ SF et al: Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a Phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Eur. J. Cancer. (1997) 33(7):1017–1024.
   PubMedGoogle Scholar
• GOSS PE, WINER EP, TANNOCK IF, SCHWARTZ LH: Randomized Phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in advanced breast cancer patients. North American Vorozole Study Group. J. Clin. Oncol. (1999) 17(1):52–63.
   PubMedGoogle Scholar
• BRODIE AM: Aromatase, its inhibitors and their use in breast cancer treatment. Pharinacol Thera. (1993) 60(3):501–515.
   PubMedGoogle Scholar
• EVANS TR, DISALLE E, ORNATI G et al.: Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. (1992) 52(205933–5939.
   Google Scholar
• LONNING PE: Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res. Treat. (1998) 49\(Suppl. 0:545–552.
   Google Scholar
• JOHANNESSEN DC, ENGAN T, DI SALLE E et al.: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a Phase I study. Clin. Cancer Res. (1997) 3(7):1101–1108.
   Google Scholar
• Aromasin® (exemestane 25 mg tablets, product information): Pfizer Canada Inc.
   Google Scholar
• GEISLER J, KING N, ANKER G et al.: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Gin Cancer Res. (1998) 4(9):2089–2093.
   Google Scholar
• LONNING PE: Aromatase inhibition for breast cancer treatment. Acta. Oncol (1996) 35\(Suppl. 5):38–43.
   Google Scholar
• MILLER WR: Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr. Relat. Cancer (1999) 6(2):187–195.
   PubMed Web of Science ®Google Scholar
• CLEMETT N, LAMB NM: Exemestane: a review of its use in post-menopausal women with breast cancer. Drugs (2000) 59(6):1279–1296.
   PubMedGoogle Scholar
• HUTSON PR, LOVE RR, CLEARY JF, KIM K: Pharmacokinetic and pharmacodynamic interaction of adjuvant tamoxifen and exemestane in postmenopausal women treated for early stage breast cancer. Breast Cancer Res. Treat. (2002) 76\(Suppl. 0:574 (Abstract 260).
   Google Scholar
• SPINELLI R, JANNUZZO MG, POGGESI I et al: Pharmacokinetics (PK) of Aromasin 9exemestane, EXE) after single and repeated doses in healthy postmehopausal volunteers (HPV). Eur. J. Cancer. (1999) 35:S295 (Abstract 1185).
   Google Scholar
• GIUDICI D, ORNATI G, BRIATICO G, BUZZENTI F, LOMBARDI P, SALLE E: 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): anew irreversible aromatase inhibitor. J. Steroid Biochein. (1988) 30(1-6):391–394.
   PubMedGoogle Scholar
• DI SALLE E, GIUDICI D, BRIATICO G,ORNATI G: Novel irreversible aromatase inhibitors. Ann. NY Acad. Sci. (1990) 595:357–367.
   PubMed Web of Science ®Google Scholar
• SOUDON J: Comparison of in-vitro exemestane activity versus other antiaromatase agents. Clin. Breast Cancer (2000) l\(Suppl. 1):568–573.
   Google Scholar
• PARIDAENS R, THOMAS J, J et al: Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a Phase I study. Anticancer Drugs.(1998) 9(8):675–683.
   PubMedGoogle Scholar
• GEISLER J, KING N, DOWSETT M, OTTESTAD L, LUNDGREN S, WALTON P et al.: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer (1996) 74(8):1286–1291.
   PubMed Web of Science ®Google Scholar
• GEISLER J, HAYNES B, ANKER G, DOWSETT M, LONNING PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Chit. Oncol (2002) 20(3):751–757.
   PubMed Web of Science ®Google Scholar
• DE JONG PC, VAN DE VEN J, NORTIER JWR et al: Inhibition of intratumoral aromatase and estradiol by exemestane in postmenopausal breast cancer patients: results of a double blind randomized study. Breast Cancer Res. Treat. (2002) 76\(Suppl. 0:576 (Abstract 268).
   Google Scholar
• ZILEMBO N, NOBERASCO C, BAJETTA E et al.: Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. BE J. Cancer. (1995) 72 (4):1007–1012.
   Google Scholar
• THURLIMANN B, PARIDAENS R, SENN D et al.: Third line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a Phase II multicentre multinational study. Exemestane Study Group. Eur. I Cancer. (1997) 33(10:1767–1773.
   PubMedGoogle Scholar
• BAJETTA E, ZILEMBO N, NOBERASCO C et al:The minimal exemestane dose for endocrine activity in advanced breast cancer.. J. Cancer. (1997) 33(4):587–591.
   Google Scholar
• COOMBES RC, HALL E, GIBSON LJ et al.: A randomised trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl..1. Med. (2004) 350(10:1081–1092.
   Google Scholar
• BAUM M, BUDZAR AU, CUZICK J et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant therapy of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysis. Cancer (2003) 98(9):1802–1810.
   PubMed Web of Science ®Google Scholar
• GOSS PE, INGLE JN, MARTINO S et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl. I Med. (2003) 349(19):1794–1802.
   Google Scholar
• JAKESZ R, JONAT W, GNANT M et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet (2005) 366(9484):455–462.
   PubMed Web of Science ®Google Scholar
• COOMBES RC, HALL E, CE BLISS JM: The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):S7 (Abstract 3).
   Google Scholar
• THURLIMANN BJ, KESHAVIAH A, MOURIDSEN H et al.: BIG 1–98: Randomized double blind Phase III study to evaluate letrozole (L) versus tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc. ASCO (2005) 23(165):6s (Abstract 511).
   Google Scholar
• POLLOW K, SCHOENEGG, KOELBL H et al.: Safety and tolerability of adjuvant exemestane plus goserelin with or without tibolone in receptor-positive, node-negative primary breast cancer in premenopausal women: The final results of the randomized multicenter ADAGIO pilot study. J. Clin. Oncol (2004) 22(14S) (Abstract 594).
   Google Scholar
• MAURIAC L, DEBLED M, DURAND M et al.: Neoadjuvant tamoxifen for hormone- non-metastatic breast carcinomas in early postmenopausal women. Ann. Oncol (2002) 13(2):293–298.
   PubMedGoogle Scholar
• EIERMANN W, PAEPKE S, APPFELSTAEDT J et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann. Oncol (2001) 12(10:1527–1532.
   PubMedGoogle Scholar
• SMITH IE, DOWSETT M, EBBS SR et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. I. Clin. Oncol (2005) 23(22):5108–5116.
   PubMed Web of Science ®Google Scholar
• MILLER WR, DIXON JM: Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control. (2002) 9\(Suppl. 2):9–15.
   Google Scholar
• TUBIANA-HULIN M, SPYRATOS F, BECETTE V et al.: Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer. Breast Cancer Res. Treat. (2003) 82\(Suppl. 1):5106 (Abstract 443).
   Google Scholar
• GIL GIL MJ, BARNADAS A, CIRERA L et al: Primary hormonal therapy with exemestane in patients with breast tumors 3 cm in diameter: Results of a Spanish Phase II trial.Oncol(2004) 22(14S) (Abstract 603).
   Google Scholar
• DALENC F, LACROIX-TRIKI M, SERONE-VIVIEN S et al.: Tamoxifen and exemestane (E) in combination as neoadjuvant treatment of hormone sensitive post-menopausal breast cancer women: Clinical efficacy and effects on tumor pathology and immunopathology. I Clin. Oncol (2004) 22(145):(Abstract 9666).
   Google Scholar
• SEMIGLAZOV VF, IVANOV VG, SEMIGLAZOV VV et al Neoadjuvant endocrine therapy versus chemotherapy for postmenopausal ER-positive breast cancer patients. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):5106 (Abstract 2090).
   Google Scholar
• CUZICK J, POWLES T, VERONESI U et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet. (2003) 361(9350296–300.
   Google Scholar
• GOSS PE, QI S, CHEUNG AM, HU H, MENDES M, PRITZKER KP: Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in rats. Clin. Cancer Res. (2004) 10(17):5717–5723.
   PubMedGoogle Scholar
• GOSS PE, THOMSEN T, BANKE-BOCHITA J, LOWERY C, ASNIS A: randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole. Breast Cancer Res. Treat. (2002) 76\(Suppl. 1):576 (Abstract 267).
   Google Scholar
• JONES S, VOGEL C, ARKHIPOV A et al: Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J. Clin. Oncol (1999) 17(11):3418–3425.
   PubMed Web of Science ®Google Scholar
• LONNING PE, BAJETTA E, MURRAY R et atActivity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. (2000) 18(11):2234–2244.
   Google Scholar
• KAUFMANN M, BAJETTA E, DIRIX LY et al.: Exemestane is superior to megesterol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomised double blind trial. (2000) 18(7):1399–1411.
   Google Scholar
• CAMERON DA, WINER E, CAMPOS S, GUASTALLA JP: A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. Clin. Oncol (2004) 22(14S): (Abstract 628).
   Google Scholar
• PARIDAENS R, DIRIX L, LOHRISCH C et al.: Mature results of a randomized Phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol (2003) 14(9):1391–1398.
   PubMed Web of Science ®Google Scholar
• PARIDAENS R, THERASSE P, DIRIX L et al: First line hormonal treatment (HT) for metastatic breast cancer (MB C) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomized Phase III trial of the EORTC Breast Group../. Clin. Oncol (2004) 22(14S): (Abstract 515).
   Google Scholar
• BERTELLI G, GARRONE O, MERLANO M.: Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc. Am. Soc. (2002) (Abstract 238).
   Google Scholar
• ARUN B, GOSS P: The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol (2004) 31(2 Suppl. 7):22–29.
   Google Scholar
• DIRIX LY, IGNACIO J, NAGS et al: Final results from an open-label, multicentre, controlled study of exemestane ± celecoxib in postmenopausal women with advanced breast cancer (ABC) progressed on tamoxifen (T). Proc. Am. Soc. Chit. Oncol (2003):20 (Abstract 77).
   Google Scholar
• CANNEY PA: Improved responses with the combination of exemestane (aromasin) with the cyclooxygenase-2 inhibitor celecoxib in postmenopausal patients with ER positive advanced breast cancer. Breast Cancer Res. Treat. (2003) 82\(Suppl. 1):S135 (Abstract 438).
   Google Scholar
• HILLNER BE, RADICE D: Cost-effectiveness analysis of exemestane compared with megesterol in patients with advanced breast carcinoma. Cancer (2001) 91(3):484–489.
   PubMed Web of Science ®Google Scholar
• LINDGREN P, JONSSON B, A, RADICE D: Cost-effectiveness analysis of exemestane compared to megesterol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics (2002) 20(2):101–108.
   PubMed Web of Science ®Google Scholar
• VERMA S, ROCCHI A: Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support. Care Cancer (2003) 11(11):728–734.
   PubMed Web of Science ®Google Scholar
• HILLNER BE: Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer (2004) 101(6):1311–1322.
   PubMed Web of Science ®Google Scholar
• DELEA TE, KARNON J, SMITH RE, BRANDMAN J, SUNG JC, GOSS PE: Cost-effectiveness of five years of extended adjuvant letrozole in postmenopausal women with early breast cancer who have completed five years of adjuvant tamoxifen. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):S58 (Abstract 1050).
   Google Scholar
• LOCKER GY, ON BEHALF OF THE ATAC TRIALISTS' GROUP: Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in women with early breast cancer from a US healthcare system perspective: the 5-year completed treatment analysis of the ATAC (Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):5105 (Abstract 2085).
   Google Scholar
• MARCHETTI M, CARUGGI M, COLOMBO G: Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Chit. Ther. (2004) 26(9):1546–1561.
   Google Scholar
• DRANITSARIS G, VERMA S, M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am. J. Clin. OncoL (2003) 26(3):289–296.
   PubMed Web of Science ®Google Scholar
• BERTELLI G, HALL E, BLISS JM, SNOWDON CE COOMBES RC: Intergroup Exemestane Study: results of the endometrial sub-protocol. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):535 (Abstract 402).
   Google Scholar
• GEISLER J, LONNING PE, KRAG LE et al.: Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: A randomized placebo-controlled study. J. Chit. Oncol (2004) 22(14S): (Abstract 531).
   Google Scholar
• SUBAR M, GOSS PE, THOMSEN T, BANKE-BOCHITA J: Effects of steroidal and non-steroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers. ./. Chit. Oncol (2004) 22(145):(Abstr 8038).
   Google Scholar
• COLEMAN RE, BANKS LM, HALL E et al.: Intergroup Exemestane Study: 1 year results of the bone sub-protocol. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):535 (Abstract 401).
   Google Scholar
• HOWELL A, CUZICK J, BAUM M et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 365(9453):60–62.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, JOSSE RG, PRITCHARD KI et al: Effect of letrozole versus placebo on bone mineral density in women completing 5 years (yrs) of adjuvant tamoxifen: ncic ctg ma.17b. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):536 (Abstract 404).
   Google Scholar
• KRAG LE, GEISLER J, LONNING PE et al: Lipid and coagulation profile in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized, placebo-controlled study. Oncol (2004) 22(145):(Abstract 650).
   Google Scholar
• ATALAY G, DIRIX L, BIGANZOLI L et al: The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized Phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. Ann. Oncol (2004) 15(2):211–217.
   PubMed Web of Science ®Google Scholar
• MARKOPOULOS C, POLYCHRONIS A, FARFARELOS C et al: The effects of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study. I Clin. Oncol (2004) 22(145):(Abstract 799).
   Google Scholar
• FALLOWFIELD LJ, PRICE MH, HALL E, COOMBES RC, BLISS JM: Intergroup exemestane study: results of the quality of life sub-protocol. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):58 (Abstract 4).
   Google Scholar
• WINER EP, HUDIS C, BURSTEIN HJ et al: American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.1 Chit. Oncol (2005) 23(3):619–629.
   Google Scholar